Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Indiplon-MR: Phase III data

In a 2-week, double-blind, U.S. Phase III trial in 229 patients, Indiplon-MR 15 mg significantly improved

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE